Catalyzing Change through Impact Investment

With multiple avenues for therapeutic intervention and cures based on the latest research, it’s clear that now is the time to invest in T1D. Our investment approach is modality agnostic, ensuring we are consistently propelling capital across a spectrum of differentiated T1D approaches with potential to accelerate treatments, prevention, and cures.

How We Invest

As an impact investment fund, we exclusively make equity investments with the same level of evaluation and investment execution approach as a traditional VC fund. We typically syndicate with experienced biotech investors and conduct diligence leveraging our extensive expertise in the space.

As we grow our portfolio, we seek differentiated, disease-modifying therapeutics and treatments with curative potential for T1D, from disease prevention to reversal, with additional interest in metabolic control and areas of high unmet need. We look at a broad range of approaches in the autoimmune & regeneration, cell replacement, and metabolic control spaces. It is our belief that there are approaches that could be relevant to T1D and have potential therapeutic application.

Geographically, our investments have spanned the globe—we believe innovation has no bounds.

Weighing Impact, Risk & Growth: Other Factors

Process

All investments are reviewed on a continuous basis, as the T1D Fund team evaluates whether each opportunity aligns with the fund’s overall strategy and mission. Post investment, we offer comprehensive support on T1D initiatives and company-wide decisions, from serving in governance roles, including Board and observer seats, to delivering strategic input on pre-clinical and clinical studies, regulatory planning, and competitive landscape analysis.

Diligence

Our team leverages its expertise alongside our Foundation partners to assess each investment opportunity and work with each company to fully understand the value proposition as well as impact.

Technology

We believe there are multiple approaches toward curative treatments for T1D and are willing to explore many different types of modalities and approaches.

R&D

We are stage agnostic and invest in discovery through clinical-stage assets; however, we seek out strong conviction around a clear product thesis that is backed by early validation.

Financing Structure

We consider traditional and novel investment structures in both private and publicly traded companies.

If you’d like to know more about our investing guidelines or want to talk to us about contributing, you can contact us here.

Supporting The Next Generation Of T1D Treatments

The T1D Fund is uniquely positioned to transform the T1D therapeutic landscape through impact investment

We invest in opportunities that reduce developmental risk, accelerate progress, and generate returns—all of which are reinvested into the Fund to fuel future investments in breakthrough T1D treatments (neither management nor donors receive distributions). Given the Fund is an affiliate of Breakthrough T1D, a 501(c)(3) organization, all donor contributions raised for the Fund are recorded as charitable donations where donors receive tax benefits at the time of contribution.

Our impact investing approach and reputation as a leader in the field enable us to attract top-tier investors and build strong syndicates to fund transformative T1D innovations.

We believe the time is now to intensify our efforts in order to become a more proactive catalyst for transformative cures and set the stage for critical impact. By continuing to be a critical thought-partner for companies, VCs and pharma, we encourage those with relevant innovative approaches to include T1D programs in their pipeline.

We remain steadfast in actively working to accelerate therapeutic development of T1D cures through equity investments. By opening the aperture of investment opportunities and catalyzing industry to focus on T1D, we can champion and broaden industry efforts towards T1D investments.

The T1D Fund’s dollars have more impact today, enabling us to up-tier our investment level by increasing our ownership in subsequent financing rounds to ensure support for T1D as an indication. Our conviction in our companies and willingness to differentially invest speaks volumes to other investors who value our expertise and insights. Now is the time to step up to orchestrate the right elevated support for our portfolio companies.